Immunovant set to land on Nasdaq via HSAC merger

Immunovant is set to land on Nasdaq through a deal with Health Sciences Acquisitions Corporation (HSAC), a business founded by RTW Investments to buy a biotech. HSAC will buy the Roivant business but the resulting company will take Immunovant’s name, management team and strategic focus.